Envelope proteome changes driven by RamA overproduction in Klebsiella pneumoniae that enhance acquired β-lactam resistance by Jiménez-Castellanos, Juan-Carlos et al.
                          Jiménez-Castellanos, J-C., Wan Ahmad Kamil, W. N. I., Takebayashi, Y.,
Findlay, J., Schneiders, T., Heesom, K. J., & Avison, M. B. (2018). Envelope
proteome changes driven by RamA overproduction in Klebsiella pneumoniae
that enhance acquired -lactam resistance. Journal of Antimicrobial
Chemotherapy, 73(1), 88-94. [dkx345]. https://doi.org/10.1093/jac/dkx345
Peer reviewed version
Link to published version (if available):
10.1093/jac/dkx345
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via OUP at https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkx345/4364866?searchresult=1.
Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 1 
The Envelope Proteome Changes Driven by RamA Overproduction in Klebsiella 1 
pneumoniae that Enhance Acquired β-Lactam Resistance. 2 
 3 
Juan-Carlos JIMÉNEZ-CASTELLANOS1, Wan Ahmad Kamil WAN NUR ISMAH1,2, Yuiko 4 
TAKEBAYASHI1, Jacqueline FINDLAY1, Thamarai SCHNEIDERS3, Kate J. HEESOM4 & Matthew B. 5 
AVISON1,* 6 
 7 
1School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom  8 
2Faculty of Biotechnology & Biomolecular Sciences, Universiti Putra Malaysia, Selangor Darul 9 
Ehsan, Malaysia. 10 
3Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, United 11 
Kingdom. 12 
4University of Bristol Proteomics Facility, Bristol. United Kingdom. 13 
 14 
*Corresponding author. Mailing address: School of Cellular and Molecular Medicine, University 15 
of Bristol, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, United Kingdom. Tel: 16 
+44(0)1173312035, Fax +44(0)1179287896. E-mail: bimba@bristol.ac.uk.  17 
 18 
Running Title: RamA enhanced β-lactam resistance in Klebsiella pneumoniae 19 
 20 
 21 
22 
 2 
Abstract  23 
OBJECTIVES 24 
In Klebsiella pneumoniae, overproduction of RamA results in reduced envelope permeability 25 
and reduced antimicrobial susceptibility but clinically relevant resistance is rarely observed. 26 
Here we have tested whether RamA overproduction can enhance acquired β-lactam 27 
resistance mechanisms in K. pneumoniae and have defined the envelope protein abundance 28 
changes upon RamA overproduction during growth in low and high osmolarity media.  29 
METHODS 30 
Envelope permeability was estimated using a fluorescent dye accumulation assay. β-Lactam 31 
susceptibility was measured using disc testing. Total envelope protein production was 32 
quantified using LC-MS/MS proteomics and transcript levels quantified by Real Time RT-PCR.  33 
RESULTS 34 
RamA overproduction enhanced β-lactamase mediated β-lactam resistance, in some cases 35 
dramatically, without altering β-lactamase production. It increased production of efflux 36 
pumps and decreased OmpK35 porin production, though micF overexpression showed that 37 
OmpK35 reduction has little impact on envelope permeability. A survey of K. pneumoniae 38 
bloodstream isolates revealed ramA hyperexpression in 3 out of 4 carbapenemase producers, 39 
1/21 CTX-M producers and 2/19 strains not carrying CTX-M or carbapenemases. 40 
CONCLUSIONS 41 
Whilst RamA is not a key mediator of antibiotic resistance in K. pneumoniae on its own, it is 42 
potentially important for enhancing the spectrum of acquired β-lactamase mediated β-lactam 43 
resistance. LC-MS/MS proteomics analysis has revealed that this enhancement is achieved 44 
predominantly through activation of efflux pump production. 45 
46 
 3 
Introduction  47 
RamA is a global transcriptional activator 1 found in, amongst other Enterobacteriaceae: 48 
Salmonella spp.,2 Enterobacter spp.1,3 and Klebsiella spp.1,4 but not Escherichia coli. Where 49 
characterised, RamA has revealed a function comparable to E. coli MarA.1-5 In wild-type 50 
Klebsiella pneumoniae, at least during standard laboratory growth, RamA production is low 51 
because the transcriptional repressor, RamR, occludes the ramA promoter.6 In some clinical 52 
isolates, RamA is overproduced due to de-repressing mutations in ramR.7-10 RamA activates the 53 
transcription of a regulon including oqxAB, acrAB and tolC, encoding components of two 54 
tripartite antimicrobial efflux pumps.4  55 
Overexpression of ramA in K. pneumoniae isolates that lack other resistance 56 
mechanisms increases MICs of a wide range of antimicrobials, including cephalosporins but not 57 
carbapenems. However, even overexpressing ramA >1000 fold only confers resistance to one or 58 
two antimicrobials and only in some isolates.5 On its own, therefore, RamA is not a key 59 
resistance determinant in K. pneumoniae, but clinical isolates can carry acquired resistance 60 
mechanisms, particularly plasmid encoded β-lactamases.11 Accordingly, the first aim of this 61 
work was to determine whether RamA overproduction can enhance the spectrum of resistance 62 
conferred by acquired β-lactamases. We also wanted to test how common ramR loss of 63 
function mutations are in K. pneumoniae clinical isolates having different β-lactam resistance 64 
phenotypes. 65 
We were particularly keen to investigate whether reduced carbapenem susceptibility 66 
occurs in RamA overproducing K. pneumoniae having ESBL or AmpC type cephalosporinases. 67 
This was because RamA overproduction and porin loss both reduce envelope permeability, and 68 
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because porin loss has previously been shown to increase carbapenem MICs against K. 69 
pneumoniae isolates producing ESBLs or AmpC cephalosporinases.12  70 
Enhancement of β-lactam MICs seen following OmpK35 porin loss in a cephalosporinase 71 
producing K. pneumoniae is reportedly minimised during growth in high osmolarity Muller 72 
Hinton media,12 which is the medium of choice for most antibiotic susceptibility testing 73 
protocols,13 but is maximised during growth in low osmolarity Nutrient media. This is because 74 
these media reportedly support different basal OmpK35 levels.12 Accordingly, we also set out to 75 
define the envelope proteome changes stimulated by RamA overproduction in Muller Hinton 76 
broth (MHB) and Nutrient broth (NB) using Orbitrap LC-MS/MS. The aim was to identify 77 
common and growth medium-specific effects of RamA overproduction, and to confirm a 78 
previous report that basal OmpK35 levels are different in the two media.12 Finally, we set out to 79 
define the contribution of RamA-mediated OmpK35 downregulation 4,5 to the overall effect of 80 
RamA overproduction on envelope permeability and antibiotic susceptibility in K. pneumoniae. 81 
 82 
Materials and Methods 83 
Bacterial strains and antibiotic susceptibility testing 84 
E. coli TOP10 (Invitrogen, Leek, The Netherlands), 44 non-replicate K. pneumoniae human 85 
clinical isolates having various antimicrobial susceptibility profiles (provided by Dr Karen 86 
Bowker, Department of Microbiology, North Bristol NHS Trust), K. pneumoniae NCTC5055 87 
transformants carrying pBAD(ramA) or a pBAD vector-only control plasmid 5 and the otherwise 88 
isogenic pair ECL8 and ECL8ΔramR 4 were used throughout. Disc susceptibility testing was 89 
performed according to CLSI methodology 13 and interpreted using CLSI performance 90 
standards.14 91 
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 92 
Cloning plasmid-mediated β-lactamase genes and micF and sequencing ramR 93 
Cloning blaNDM-1 (with its ISAba125 promoter) into the cloning vector pSU18 15 has previously 94 
been reported.16 K. pneumoniae micF and the following additional β-lactamase genes were 95 
synthesised or amplified by PCR from the sources and using the primers listed in Table S1 and 96 
the PCR method previously described 17 in such a way as to include their native promoters: 97 
blaIMP-1 and blaVIM-1 (with hybrid and weak strength class 1 integron promoters, respectively),18 98 
blaCTX-M1 and blaCMY-4 (with ISEcp1 promoters), blaKPC-3 (with ISKpn7 promoter) and blaOXA-48 99 
(with IS1999 promoter). Some PCR amplicons were TA cloned into the pCR2.1-TOPO cloning 100 
vector (Invitrogen) according to the manufacturer’s instructions. These pCR2.1 inserts, removed 101 
by restriction enzyme digestion, and other PCR amplicons directly cut with restriction enzymes, 102 
were ligated into the pSU18 15 or pK18 19 cloning vectors as illustrated in Table S1. Plasmids 103 
were used to transform K. pneumoniae isolates to chloramphenicol or kanamycin (30 mg/L) 104 
resistance for pSU18 and pK18, respectively, using electroporation as standard for lab strain E. 105 
coli. To sequence ramR from clinical isolates, the gene was amplified using PCR as previously 17 106 
and sequenced; primers are recorded in Table S1. Sequence alignment and analysis were 107 
performed using the online ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/) tool; the 108 
reference sequence used was K. pneumoniae Ecl8 (Accession Number HF536482.1). 109 
 110 
Growth of cultures for all experiments 111 
Each isolate or transformant was inoculated into a separate batch of 50 mL Cation Adjusted 112 
MHB (Sigma) or NB (Oxoid) containing appropriate selection in a 250 mL foam stoppered flask 113 
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to an initial Optical Density at 600 nm (OD600) of ≈0.05. Cultures were incubated with shaking 114 
(160 rpm) until the OD600 had reached 0.5-0.7.  115 
 116 
Fluorescent Hoechst (H) 33342 dye accumulation assay 117 
Envelope permeability was estimated as described previously 5 in bacteria grown in liquid 118 
culture using an established fluorescent dye accumulation assay 20 with black flat-bottomed 96-119 
well plates (Greiner Bio-one, Stonehouse, UK) and a Fluostar Optima (Aylesbury, UK) plate 120 
reader. H33342 (Sigma) was used at a final concentration of 2.5 μM.  121 
 122 
Characterisation of Envelope Proteomes and Real-Time RT-PCR 123 
Methods used for protein and RNA extraction and analysis of abundance were almost identical 124 
to those used previously 5 and are presented in detail in Supplementary Material. For each LC-125 
MS/MS proteomics experiment, raw protein abundance data were collected for three biological 126 
replicates of each growth condition. The significance of any observed difference between the 127 
means of the triplicate abundance data for one protein in two different growth conditions was 128 
calculated using a T-test comparing the raw abundance data as described in Supplementary 129 
Material. 130 
 131 
β-Lactamase assays and multiplex PCR for β-lactamase gene carriage. 132 
Multiplex PCRs were performed for (i) carbapenemase genes encoding the IMP, VIM, OXA-48-133 
like, NDM and KPC enzymes,21 though the NDM and OXA-48-like gene-identifying PCRs were 134 
run separately and not as a multiplex with the rest (ii) genes encoding CTX-M groups 1, 2, 8, 9 135 
and 25 22 (iii) a bespoke multiplex for genes encoding TEM-1, SHV, OXA-1 and CMY. All 136 
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multiplex PCR primers and expected product sizes are recorded in Table S2. DNA template was 137 
prepared as previously described 17 and 1 µL of supernatant used in a final PCR reaction volume 138 
of 25 µL consisting of 12.5 µL REDTaq ReadyMix (Sigma) with 10 µM of each primer. PCR was 139 
performed using the following conditions: 94°C for 10 min, 35 cycles of amplification consisting 140 
of 94°C for 1 min, 52-56°C for 1 min, 72°C for 1 min 30 s and a final extension at 72°C for 10 141 
min. 142 
β-Lactamase assays were performed as follows: overnight cultures of bacteria were 143 
diluted to an optical density at 600 nm (OD600) of 0.1 in MHB and grown at 37°C until the 144 
OD600 was 0.8 before cell extracts were prepared and levels of β-lactamase activity in cell 145 
extracts measured as described previously 23 using 100 μM nitrocefin as substrate. Linear 146 
gradients (ΔAU/min) were extrapolated and an extinction coefficient of 17,400 AU/M was used 147 
to calculate nitrocefin hydrolysing activity. The total protein concentration in each cell extract 148 
was quantified using the Bio-Rad protein assay reagent (Bio-Rad, Hemel Hempstead, United 149 
Kingdom) according to the manufacturer's instructions and used to calculate relative specific 150 
enzyme activity (pmol/min/µg) in each cell extract.  151 
 152 
Results and Discussion 153 
Enhancement of β-lactam resistance in K. pneumoniae by RamA in the presence of acquired β-154 
lactamases 155 
A library of seven clinically important mobile β-lactamase genes was created using 156 
pSU18, a low copy number vector.15 Each gene was expressed from a promoter commonly seen 157 
in clinical isolates to give close to wild-type levels of β-lactamase production (see table S1). This 158 
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library was used to transform K. pneumoniae Ecl8 and Ecl8ΔramR, and there was no significant 159 
difference in β-lactamase production in Ecl8ΔramR versus Ecl8 transformants (Table S3).  160 
Ecl8 is susceptible to 17/18 tested β-lactams (Table 1). Overproduction of RamA (i.e. 161 
Ecl8ΔramR) reduced zone diameters ≥2 mm for 13/18 tested β-lactams, but clinically relevant 162 
non-susceptibility 14 was not achieved for any of them (Table 1). The metallo-β-lactamases 163 
(MBLs) NDM-1 and IMP-1 rendered Ecl8 non-susceptible to 17/18 and 14/18 β-lactams, 164 
respectively, so the additional effect of RamA overproduction was difficult to see (Table 1). 165 
Accordingly, blaVIM-1 was cloned with a weak integron promoter and the resultant low-level 166 
MBL production meant that Ecl8 remained susceptible to 12/18 test β-lactams. Here, the effect 167 
of RamA overproduction was profound. Ecl8ΔramR (VIM-1) was only susceptible to aztreonam 168 
and cefotetan (Table 1). 169 
RamA overproduction also affected β-lactam susceptibility in the presence of serine β-170 
lactamases (SBLs). There was a considerable zone diameter reduction for ertapenem (by 7 mm; 171 
on the verge of being non-susceptible) in Ecl8ΔramR (CTX-M1) versus Ecl8 (CTX-M1) but for the 172 
other carbapenems, no change at all. In the case of the AmpC-type SBL, ertapenem non-173 
susceptibility was conferred in Ecl8ΔramR (CMY-4), though the other carbapenems remained 174 
equally active as against Ecl8 (CMY-4). In Ecl8 (KPC-3), only the cephamycins retained activity, 175 
but even these were lost in Ecl8ΔramR (KPC-3). In contrast, the effect of carrying OXA-48 was 176 
relatively weak. When RamA was overproduced there was a slight reduction in inhibition zone 177 
diameter, particularly for the carbapenems, but Ecl8ΔramR(OXA-48) remained susceptible to 178 
17/18 β-lactams (Table 1).  179 
 180 
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A survey of ramR function in clinical isolates carrying or not carrying cephalosporinases and 181 
carbapenemases. 182 
Forty-four K. pneumoniae clinical isolates were randomly collected (Table S4). Twenty isolates 183 
carried a ramR allele encoding a Thr141Ile variant (in comparison with Ecl8) which has no 184 
impact on phenotype.9 Two isolates encoded the Ala19Val RamR variant which is also 185 
functionally silent.24 Seven other isolates encoded RamR protein variants and Real-Time RT-PCR 186 
was used to measure ramA transcript levels in in these seven isolates comparison with the 187 
ramR wild-type isolate AH. Six of the RamR variant isolates hyper-expressed ramA; the 188 
Ile106Ser variant was not associated with significantly higher ramA expression (Table S4).  189 
Three multiplex PCRs were performed to categorise the β-lactamase genes present in 190 
each of the 44 clinical isolates. Four carried at least one carbapenemase gene, of which two 191 
also carried blaCTX-M; 21 additional isolates carried blaCTX-M. All CTX-M genes were of group 1. 192 
The remaining 19 isolates did not carry any cephalosporinase or carbapenemase gene (Table 193 
S4). 194 
Finally, disc susceptibility testing was performed for eight β-lactams against the 44 195 
clinical isolates. Using the sum of all the inhibition zone diameters to represent the combined β-196 
lactam susceptibility for each isolate, we ranked the isolates (Table S4). Not surprisingly, the 197 
four carbapenemase positive isolates were the four least β-lactam susceptible. Interestingly, 198 
three out of four of these isolates also carry a ramR mutation and hyperexpress ramA. Only one 199 
of the 21 carbapenemase negative, CTX-M positive isolates hyperexpressed ramA, but this 200 
isolate (isolate T) was by far the least susceptible isolate in this group. As predicted from our 201 
transformation experiments, isolate T displayed reduced carbapenem susceptibility relative to 202 
the 20 isolates that have CTX-M but an intact ramR. However, this effect (Table S4) was greater 203 
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than that seen in the Ecl8/Ecl8ΔramR transformants (Table 1), with resistance to ertapenem, 204 
and intermediate resistance to doripenem being observed in isolate T, together with reduced 205 
susceptibility to meropenem suggesting an additional as yet uncharacterised mechanism in 206 
isolate T. As seen with Ecl8ΔramR (Table 1), ramA hyperexpression in the two clinical isolates 207 
(isolates N and AO) that lack any cephalosporinase or carbapenemase genes had minimal 208 
impact on β-lactam susceptibility (Table S4) 209 
 210 
Envelope Proteome Changes Following RamA Overproduction in K. pneumoniae in NB and MHB 211 
and Impact on Envelope Permeability 212 
We have recently shown that RamA overproduction in K. pneumoniae NCTC5055 using a pBAD 213 
expression plasmid increased AcrAB-TolC and OqxAB-TolC efflux pump production.5 To obtain a 214 
more detailed understanding of the RamA regulon, we used Orbitrap LC-MS/MS proteomics. 215 
Table S5 shows summary data for the Ecl8/Ecl8ΔramR pair during growth in MHB. It has 216 
previously been reported that low osmolarity media such as NB affect the levels of OmpK35 217 
relative to growth in high osmolarity media such as MHB.12 This observation is potentially 218 
important because OmpK35 levels might impact on envelope permeability and because 219 
antimicrobial susceptibility assays are generally performed using Muller-Hinton media. 220 
Accordingly, to see whether medium osmolarity affects the impact of RamA overproduction, 221 
we also determined envelope proteome changes in the Ecl8/Ecl8ΔramR pair during growth in 222 
NB (Table S6).  223 
Our LC-MS/MS methodology allowed identification and absolute quantification with a 224 
high degree of certainty (≥ 3 peptides identified) of 655 and 494 proteins in envelope 225 
preparations from cells grown in MHB and NB, respectively. Previous data from SDS-PAGE 226 
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analysis of outer membrane protein preparations have been interpreted as meaning that 227 
OmpK35 levels increase relative to OmpK36 levels upon shifting from MHB to NB,12 and our LC-228 
MS/MS data confirmed this finding. There is a shift in the OmpK36:OmpK35 ratio in Ecl8 from 229 
1.7:1 (calculated from mean protein abundance data, p=0.013, n=3) during growth in MHB to 230 
1.1:1 (p=0.45, n=3) during growth in NB. Our accurate absolute abundance data revealed that 231 
this change in OmpK36:OmpK35 ratio is achieved through downregulation of OmpK36 (2.2-fold, 232 
p=0.011, n=3) not upregulation of OmpK35 (0.7-fold, p=0.16, n=3) during growth in NB relative 233 
to growth in MHB.  234 
Twenty-nine and 33 proteins were found to be ≥ 2-fold up or down regulated in 235 
Ecl8ΔramR versus Ecl8 following application of our statistical significance cut-off (p<0.05 for a T-236 
test comparing absolute protein abundance data, n=3) during growth in MHB and NB, 237 
respectively (Tables S5, S6). Of these, 12 proteins were similarly regulated in both media; 11 238 
upregulated, with only OmpK35 downregulated (Table 2). Ten out of 11 proteins upregulated in 239 
Ecl8ΔramR in both media were also upregulated in K. pneumoniae strain NCTC5055 following 240 
overproduction of RamA via the pBAD expression plasmid (Table S7). These 10 core 241 
upregulated proteins represent two efflux pumps (AcrAB and OqxAB, together with the outer 242 
membrane efflux protein TolC). The remaining proteins are poorly characterised and neither 243 
their precise role in RamA mediated reduced antimicrobial susceptibility, nor their direct 244 
control by RamA can be confirmed at this time. 245 
Of the medium-specific impacts of RamA overproduction, two are striking. In MHB only, 246 
downregulation of several proteins encoded by the maltose transport operon occurs (Table S5). 247 
The LamB2 porin is amongst these. Interestingly, its loss by mutation has been implicated in 248 
reduced carbapenem entry in K. pneumoniae,25,26 so it is conceivable that downregulation of 249 
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LamB2 might enhance the impact of RamA overproduction on carbapenem MICs during growth 250 
on Muller-Hinton agar, which is apparent in the presence of certain plasmid-mediated β-251 
lactamases (Table 1, Table S4). In NB only, the efflux pump AcrEF is upregulated in Ecl8ΔramR 252 
relative to Ecl8. Whilst this pump has not been specifically characterised in K. pneumoniae, its 253 
equivalent has a role in antimicrobial resistance in other enteric bacteria, and it is part of the 254 
Salmonella Typhimurium RamA regulon.2 Also upregulated in NB only is the transporter 255 
complex proteins YrbCDEF (Table S6). RamA-mediated regulation of the yrb locus has previously 256 
been demonstrated using transcriptome analyses in both K. pneumoniae 4 and S. Typhimurium 257 
2 and a potential RamA binding site has been proposed for the yrb locus in K. pneumoniae.4 258 
YrbCDEF from Ecl8 are >90% identical to the MlaCDEF proteins, part of the MlaABCDEF ABC 259 
transporter from E. coli, which has recently been shown to play an important role in retrograde 260 
phospholipid trafficking. The perturbation of the phospholipid content of the outer membrane 261 
is likely to result in a reduction in its sensitivity to chemical damage, and may also affect 262 
antimicrobial/cell affinity, reducing rate of entry.27-29 The AcrEF and Yrb (Mla) proteins were 263 
also upregulated following RamA overproduction from the pBAD expression vector in K. 264 
pneumoniae NCTC, but LamB2 is not downregulated (Table S7). These NCTC5055 data were 265 
collected during growth in NB, which explains these findings, and confirms the medium 266 
dependence of the effects. 267 
Despite these differences in envelope proteome seen during growth of Ecl8ΔramR in 268 
MHB and NB, there is little impact of growth medium on RamA-mediated envelope 269 
permeability reduction. When measured using fluorescent dye accumulation, envelope 270 
permeability reduces by ≈75% in Ecl8ΔramR versus Ecl8 during growth in MHB and ≈65% during 271 
growth in NB (Fig. 1A). 272 
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Overall, based on our test of significance, 51 proteins were differentially regulated in 273 
NCTC5055 carrying pBAD(ramA) versus the pBAD control transformant during growth in the 274 
presence of 0.2% w/v arabinose, which stimulates RamA overproduction (Table S7). This is 275 
more than the number of proteins differentially regulated in Ecl8ΔramR versus Ecl8 (Tables S5, 276 
S6). However, according to Real Time RT-PCR analysis, there was 9200 +/- 390 fold (mean +/- 277 
SEM, n=3) more ramA transcript in NCTC5055::pBAD(ramA) than in NCTC5055::pBAD(control) 278 
when grown in the presence of 0.2% (w/v) arabinose, as shown previously.5 This is dramatically 279 
more than that seen for the “natural” RamA overproducing mutant Ecl8ΔramR, where there is 280 
6.7 +/- 2.2 fold (mean +/- SEM, n=3) more ramA transcript than in Ecl8, and ≈100-fold more 281 
than even the most ramA overexpressing clinical isolate in our collection (Table S4). Hence the 282 
additional proteomic differences seen in NCTC:pBAD(ramA) are likely to be due to spurious 283 
occupation of regulatory binding sites by the greatly overproduced RamA, which has previously 284 
been reported in Salmonella.2  285 
 286 
Role of micF in RamA Mediated Control of OmpK35 Levels. 287 
There is clear downregulation of OmpK35 porin production following RamA overproduction in 288 
Ecl8 (Table 2). By analogy with the situation in E. coli following overproduction of MarA,30 289 
reduction of OmpK35 levels in K. pneumoniae is likely to be due to transcriptional upregulation 290 
of micF by RamA. To test this, we cloned the micF gene, with its own promoter into a high-copy 291 
vector pK18 19 and used this recombinant to boost micF transcript levels in trans in Ecl8. LC-292 
MS/MS confirmed that OmpK35 levels were downregulated (0.39 fold, p=0.005, n=3) in 293 
Ecl8(micF) compared with Ecl8(pK18) during growth in MHB; almost the same downregulation 294 
seen in Ecl8ΔramR compared with Ecl8 during growth in MHB (0.43 fold, p=0.007, n=3). 295 
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However, dye accumulation assays unexpectedly revealed that steady-state accumulation of 296 
the fluorescent dye is approximately 20% more in Ecl8(micF) than in the Ecl8(pK18) control 297 
transformant, suggesting an increase in envelope permeability in the micF overexpressing 298 
recombinant (Fig 1B). Disc susceptibility testing confirmed that this is sufficient to increase 299 
antibiotic inhibition zones against Ecl8(micF) (Table S8).  300 
We hypothesised that the reason for this increase in envelope permeability (Fig. 1B) 301 
despite OmpK35 levels being reduced is that K. pneumoniae responds by downregulating efflux 302 
pump production or upregulating porin production to balance envelope permeability. A 303 
reciprocal effect: downregulation of OmpK35 in K. pneumoniae having reduced AcrAB-TolC-304 
mediated efflux has recently been reported.31 In support of our hypothesis, Real Time RT-PCR 305 
showed that acrA levels are reduced in Ecl8(micF) versus Ecl8(pK18) (0.53 +/- 0.07-fold [mean 306 
+/- SEM, n=3]); LC/MS-MS confirmed that this led to a reduction in AcrA protein levels (0.62-307 
fold, p=0.05, n=3). No porin proteins were seen to be upregulated in the proteomics data (not 308 
shown). In fact, OmpK36 and OmpA are downregulated (respectively, 0.57-fold, p=0.02, n=3 309 
and 0.61-fold, p=0.03, n=3). 310 
Interestingly, downregulation of ramA transcription was seen using Real Time RT-PCR in 311 
Ecl8(micF) compared with Ecl8(pK18) (0.09 +/- 0.04-fold [mean +/- SEM, n=3]). It is possible, 312 
therefore, that RamA downregulation may be responsible for the downregulation of AcrA seen 313 
in response to micF-mediated OmpK35 downregulation. If correct, this is suggestive of a 314 
feedback mechanism by which the cell can sense the balance of different factors affecting 315 
envelope permeability and controls RamA production as necessary. 316 
 317 
 318 
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Conclusions 319 
RamA overproduction in K. pneumoniae has been associated with resistance to specific 320 
antimicrobials, e.g. tigecycline.9,24 We conclude that RamA overproduction is predominantly 321 
mediated by efflux pump overproduction and can also be selected in isolates with acquired β-322 
lactamases, which are very common in the clinic. The effect on carbapenem resistance in K. 323 
pneumoniae carrying a weakly expressed blaVIM-1 gene was particularly pronounced, and it was 324 
striking to see ramA hyperexpression in 3/4 carbapenemase producing bloodstream isolates 325 
from a collection (Table S4). It was also particularly concerning to see the generation of 326 
ertapenem resistance following loss of RamR repressor activity in combination with an AmpC-327 
type enzyme in Ecl8 (Table 1) and in a ramA overexpressing clinical isolate carrying CTX-M 328 
(Table S4). There may be other ways by which RamA overproduction can be beneficial; for 329 
example, it may be a prerequisite for the selection of other resistance-causing mutation events 330 
such as target site mutations or those which cause porin loss. 331 
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Table 1 MICs of β-lactams against K. pneumoniae Ecl8 and Ecl8ΔramR transformants carrying 435 
clinically important β-lactamase genes. 436 
 
pSU18 IMP-1 NDM-1 VIM-1 CTX-M1 CMY-4 KPC-3 OXA-48 
Antibiotic (µg) Ecl8 Δ Ecl8 Δ Ecl8 Δ Ecl8 Δ Ecl8 Δ Ecl8 Δ Ecl8 Δ Ecl8 Δ 
Ampicillin (10) 16 10 6 6 6 6 6 6 11 6 6 6 6 6 12 6  
Piperacillin (100) 29 25 27 22 9 6 22 15 15 6 17 14 8 6 28  26  
Piperacillin/         
Tazobactam (110) 
32 26 30 22 8 6 22 15 30 25 25 20 16 8 30  28 
Cefotetan (30) 32 30 15 6 14 6 30 22 30 28 17 14 21 13  31 27 
Cefoxitin (30) 30 23 6 6 6 6 22 15 28 23 11 6 23 10  28 20 
Cefuroxime (30) 32 22 6 6 6 6 12 6 16 6 6 6 6 6  30 21 
Cefotaxime (30) 40 32 20 12 6 6 22 15 15 6 15 12 19 10 39  32 
Ceftriaxone (30) 38 33 19 14 6 6 25 16 16 6 15 10 13 6 35  32  
Ceftazidime (30) 33 30 15 6 6 6 19 11 20 15 13 7 14 6  31 29 
Cefoperazone (75) 34 29 19 15 10 6 22 15 17 6 22 20 11 8  30 26 
Ceftizoxime (30) 40 35 20 15 6 6 25 19 30 15 18 16 20 11  40 33 
Cefixime (5) 33 29 14 6 6 6 18 6 16 6 6 6 17 6 31  27 
Cefepime (30) 36 36 25 20 18 10 26 20 22 15 37 33 19 11  35 31 
Aztreonam (30) 40 38 40 37 40 38 40 37 19 15 18 15 12 6  38 33 
Doripenem (10) 30 30 20 18 15 10 23 21 30 30 26 26 16 16  28 28 
Ertapenem (10) 30 30 20 15 10 6 26 20 29 22 23 20 17 9 24  22 
Imipenem (10) 30 30 16 16 14 10 19 19 30 30 30 30 14 11 26  25 
Meropenem (10) 30 30 18 15 8 8 23 20 30 30 31 31 18 12 30  27 
 437 
Assays were performed using Muller Hinton agar according to the CLSI protocol 13 for K. 438 
pneumoniae Ecl8 and Ecl8ΔramR (Δ). Values reported are the means of three repetitions 439 
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rounded to the nearest integer. Zones confirming non-susceptibility are shaded grey. 440 
Susceptibility breakpoints are as set by the CLSI.14 441 
442 
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443 
Table 2. Significant Changes in Envelope Protein Abundance Seen in Ecl8ΔramR versus Ecl8 444 
During Growth in Both MHB and NB 445 
 446 
 447 
Methodology and details of data analysis are described in Supplementary Material. Where 448 
protein goes from being undetectable to being detectable in parent versus mutant, a nominal 449 
fold change of >20 and a p value of <0.001 have been applied, as described.5 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
469 
Accession Description 
MHB NB 
p value Fold 
Change 
p value Fold 
Change 
A6T5M4 AcrB 0.038 4.87 0.044 6.21 
A6T5M5 AcrA 0.002 3.88 0.002 3.38 
A6T5Q5 Putative Outer Membrane Protein <0.001 5.85 <0.001 >20 
A6T6W3 Putative lipoprotein YbjP 0.001 5.30 0.002 7.01 
A6T721 OmpK35 0.007 0.43 0.026 0.23 
A6T7Z9 ABC Transporter SapF <0.001 >20 <0.001 >20 
A6T8F9 Heat shock protein HslJ <0.001 >20 <0.001 >20 
A6T9Y7 Putative uncharacterized protein YdhA 0.021 6.17 <0.001 >20 
A6TCQ4 OqxA <0.001 >20 <0.001 >20 
A6TCQ5 OqxB <0.001 >20 <0.001 >20 
A6TCT2 Putative Uncharacterized Protein 0.012 4.06 <0.001 5.03 
A6TE24 TolC 0.004 3.15 0.013 3.51 
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Figure Legends  470 
 471 
Figure 1: Effect of RamA Overproduction or micF Overexpression in K. pneumoniae Ecl8 on 472 
Envelope Permeability in Different Growth Media. 473 
The accumulation of H33342 dye over a 30 cycle (45 minute) incubation period by (A) K. 474 
pneumoniae Ecl8ΔramR compared with Ecl8 (set to 100%) grown in (solid line) NB and (dashed 475 
line) MHB. (B) K. pneumoniae Ecl8(micF) compared with Ecl8(control) (set to 100%) grown in 476 
MHB. Each line shows mean data for three biological replicates with 8 technical replicates in 477 
each, and error bars define the standard error of the mean (SEM). 478 
 479 
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Figure 1 
A 
 
B 
 
The Envelope Proteome Changes Driven by RamA Overproduction in Klebsiella 480 
pneumoniae that Enhance Acquired β-Lactam Resistance. 481 
 482 
Supplementary Data 483 
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 484 
SUPPLEMENTARY METHODS 485 
Proteomic Analysis 486 
Cells in cultures were pelleted by centrifugation (10 min, 4,000 × g, 4˚C) and resuspended in 20 487 
mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 sec on, 0.5 sec off for 3 488 
min at amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and Materials Inc., Newton, 489 
Connecticut, USA). The sonicated samples were centrifuged at 8,000 rpm (Sorval RC5B PLUS 490 
using an SS-34 rotor) for 15 min at 4˚C to pellet intact cells and large cell debris. The 491 
supernatant was removed and subjected to centrifugation at 20,000 rpm for 60 min at 4˚C 492 
using the above rotor to pellet total envelopes. To isolate total envelope proteins, this total 493 
envelope pellet was solubilised using 200 μL of 30 mM Tris-HCl pH 8 containing 0.5% (w/v) SDS. 494 
The protein concentration in each sample was quantified using Biorad Protein Assay Dye 495 
Reagent Concentrate according to the manufacturer’s instructions. Proteins (5 μg/lane) were 496 
separated by SDS-PAGE using 11% acrylamide, 0.5% bis-acrylamide (Biorad) gels and a Biorad 497 
Min-Protein Tetracell chamber model 3000X1. Gels were resolved at 200 V until the dye front 498 
had moved approximately 1 cm into the separating gel. Proteins in all gels were stained with 499 
Instant Blue (Expedeon) for 20 min and de-stained in water.  500 
The one centimeter of gel lane containing total envelope proteins was cut out and subjected to 501 
in-gel tryptic digestion using a ProGest automated digestion unit (Digilab UK).  The resulting 502 
peptides were fractionated using an Ultimate 3000 nanoHPLC system in line with an LTQ-503 
Orbitrap Velos mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid 504 
were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 505 
washing with 0.5% (v/v) acetonitrile plus 0.1% (v/v) formic acid, peptides were resolved on a 506 
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250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over 507 
a 150 min organic gradient, using 7  gradient segments (1-6% solvent B over 1 min., 6-15% B 508 
over 58 min., 15-32% B over 58 min., 32-40% B over 3 min., 40-90% B over 1 min., held at 90% B 509 
for 6 min and then reduced to 1% B over 1 min.) with a flow rate of 300 nl.min−1.  Solvent A 510 
was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides 511 
were ionized by nano-electrospray ionization at 2.1 kV using a stainless steel emitter with an 512 
internal diameter of 30 μm (Thermo Scientific) and a capillary temperature of 250°C. Tandem 513 
mass spectra were acquired using an LTQ-Orbitrap Velos mass spectrometer controlled by 514 
Xcalibur 2.1 software (Thermo Scientific) and operated in data-dependent acquisition mode. 515 
The Orbitrap was set to analyze the survey scans at 60,000 resolution (at m/z 400) in the mass 516 
range m/z 300 to 2000 and the top twenty multiply charged ions in each duty cycle selected for 517 
MS/MS in the LTQ linear ion trap. Charge state filtering, where unassigned precursor ions were 518 
not selected for fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30 s; 519 
exclusion list size, 500) were used. Fragmentation conditions in the LTQ were as follows: 520 
normalized collision energy, 40%; activation q, 0.25; activation time 10 ms; and minimum ion 521 
selection intensity, 500 counts. 522 
The raw data files were processed and quantified using Proteome Discoverer software v1.2 523 
(Thermo Scientific) and searched against the UniProt K. pneumoniae strain ATCC 700721 / MGH 524 
78578 database (5126 protein entries; UniProt accession 272620) using the SEQUEST (Ver. 28 525 
Rev. 13) algorithm. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance 526 
was set at 0.8 Da. Search criteria included carbamidomethylation of cysteine (+57.0214) as a 527 
fixed modification and oxidation of methionine (+15.9949) as a variable modification. Searches 528 
were performed with full tryptic digestion and a maximum of 1 missed cleavage was allowed. 529 
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The reverse database search option was enabled and all peptide data was filtered to satisfy 530 
false discovery rate (FDR) of 5 %. The Proteome Discoverer software generates a reverse 531 
“decoy” database from the same protein database used for the analysis and any peptides 532 
passing the initial filtering parameters that were derived from this decoy database are defined 533 
as false positive identifications. The minimum cross-correlation factor filter was readjusted for 534 
each individual charge state separately to optimally meet the predetermined target FDR of 5 % 535 
based on the number of random false positive matches from the reverse decoy database. Thus, 536 
each data set has its own passing parameters. Protein abundance measurements were 537 
calculated from peptide peak areas using the Top 3 method S1 and proteins with fewer than 538 
three peptides identified were excluded.  539 
Proteomic analysis was repeated three times for each test condition, each using a separate 540 
batch of cells. Data analysis was as follows: raw protein abundance data were uploaded into 541 
Microsoft Excel. A paired T-test was used to calculate the significance of any difference in 542 
protein abundance data in pooled data from the two test conditions; where protein abundance 543 
was below the level of detection the value was excluded and not set to zero. A p-value of <0.05 544 
was considered significant. The fold change in abundance for each protein in two test 545 
conditions was calculated using the averages of absolute abundances for the three biological 546 
replicates for the two test conditions. All raw protein abundance data are provided in the 547 
attached proteomics data file. 548 
 549 
Quantitative Reverse-Transcriptase PCR 550 
RNA in cultures was stabilised using RNAprotect Bacteria Reagent (Qiagen, Crawley, UK) 551 
according to the manufacturer’s instructions, before 1.5 mL of stabilised culture was 552 
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centrifugation for 5 min at 4000 rpm (Function Line Labofuge 400R centrifuge, Heraeus, Hanau, 553 
Germany) to pellet cells. Following aspiration of the supernatant, 200 µL of TE buffer containing 554 
lysozyme (50 mg/mL) was used to disrupt the pellet, and the mixture was left for 10 min at 555 
room temperature, vortexing every 2 min before addition of 700 μL RLT buffer (Qiagen) 556 
containing 150 mM β-mercaptoethanol. The mixture was transferred to a tube containing acid 557 
washed silica lysing matrix B (MP Biochemicals, Eschwege, Germany) and cells were disrupted 558 
in a Ribolyser (Hybaid, Basingstoke, UK) (setting 6.0; 2 cycles lasting 45 s each). Following 559 
disruption, RNA was purified using a Qiagen RNeasy RNA purification kit, according to the 560 
manufacturer’s instructions. RNA from 1.5 mL of bacterial culture was dissolved in 50 μL RNase 561 
free water, contaminating genomic DNA was digested using a TURBO DNA-free™ Kit (Ambion, 562 
Foster City, CA, USA) following the manufacturer’s instructions. The concentration of RNA in 563 
each sample was measured using a NanoDrop ND-100 spectrophotometer (Labtech, UK). One 564 
microgram of total RNA was converted into cDNA using qScriptTM reverse transcriptase (Quanta 565 
Biosciences, Gaithersburg, MD, USA) in a 20 μL reaction which included random hexamer 566 
primers. The reaction was incubated for 5 min at 25°C, 30 min at 42°C and 5 min at 85°C. cDNA 567 
samples were stored at -20°C until used as templates for gene-specific real-time qPCR. The 568 
reference gene in each case was rrsE. Each real-time qPCR reaction was prepared using 100 ng 569 
of cDNA (quantified by Nanodrop) as template in a 20 μL reaction with PowerUp™ SYBR Green 570 
Master Mix (Applied Biosystems, Waltham, Massachusetts, USA) and 500 nM of each primer. 571 
Primers are listed in the supplementary table of our previous paper.S2 The amplification and 572 
quantification of cDNA copies was performed using a StepOnePlus™ Real-Time PCR System 573 
(Applied Biosystems). Samples were run as 4 technical replicates and 3 biological replicates 574 
were used for each comparison, each from RNA purified from a separate batch of cells. The PCR 575 
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amplification cycles consisted of initial denaturation at 95°C for 2 min followed by 40 cycles of 576 
denaturation at 95°C for 2 s and annealing/extension at 60°C for 30 s. The ratio of target to 577 
reference cDNA in a sample of comparator B was calculated relative to that in a sample of 578 
comparator A according to the ΔΔCT method.S3 In each case, comparator A was set as the 579 
control. 580 
 581 
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SUPPLEMENTARY TABLES 601 
 602 
Table S1. Cloning strategies and PCR primers used. 603 
Primer Sequence (5’ to 3’) Cloning strategy 
blaIMP-1 F GCCTGTTCGGTTCG PCR amplification from Pseudomonas aeruginosa clinical 
isolate 206-3105A clinical isolate (a gift from Dr Mark 
Toleman, Cardiff University). Sequence as in Genbank 
accession number AP012280.1. Amplicon TA-cloned into 
pCR2.1-TOPO and subcloned using EcoRI into pSU18. 
bla IMP-1 R AGCGAAGTTGATATGTATTGTG 
blaVIM-1 F ACCCAGTGGACATAAGCCTG PCR amplified from a K. pneumoniae clinical isolate (a gift 
from Dr Jim Spencer, University of Bristol). Sequence as in 
Accession number GQ422829.1. TA-cloned into pCR2.1-TOPO 
and subcloned using EcoRI into pSU18. 
bla VIM-1 R TCTGCTACTCGGCGACTGAG 
blaCTX-M-1 F  AATACTACCTTGCTTTCTGA PCR amplification from an E. coli clinical isolate (a gift from 
Professor Peter Hawkey, University of Birmingham). Sequence 
as in Accession number AM003904. Amplicon TA-cloned into 
pCR2.1-TOPO and subcloned using EcoRI into pSU18. 
blaCTX-M-1 R GGTGGCATAATTTTGAAGT 
blaCMY-4 F  CTGCAGAATTCGCCCTTCATTGC
AGCAAAGATGAAA 
PCR amplification from a K. pneumoniae clinical isolate (a gift 
from Dr Jim Spencer, University of Bristol). Sequence as in 
Genbank accession number NG_036465.1. Amplicon digested 
with EcoRI (sites underlined in the primer sequence) and 
directly ligated into pSU18. 
blaCMY-4 R TGTGCTGGAATTCGCCCTTGTT
ATTTACCACGGTAACGC 
blaKPC-3 F ACCCTTGCCATCCCGTGTGC PCR amplified from a K. pneumoniae clinical isolate (a gift 
from Dr Jim Spencer, University of Bristol). Sequence as in 
Genbank accession number EU176011.1. Amplicon TA-cloned 
into pCR2.1-TOPO and subcloned using EcoRI into pSU18. 
blaKPC-3 R CGCCATCGTCAGTGCTCTAC 
blaOXA-48 F GAATTCGAGCAAACGATC Gene synthesised as in Accession number NC_019154.1 with 
the addition of flanking EcoRI sites and ligated into vector 
pEX-A2. Sequence in previous column shows the ends of the 
synthesised sequence plus EcoRI sites (underlined). Subcloned 
into pSU18 using EcoRI. 
blaOXA-48 F GAATTCGAATTCCCTAGCA 
micF F CATATCTATAGCACTGAATGG PCR amplified from K. pneumoniae Ecl8. Amplicon TA cloned 
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micF R TAAAGAAGGGTAAAAAAAAGC
G 
into pCR2.1-TOPO and subcloned using EcoRI into pK18 
ramR F CTGCAGTGCCCGGTGAACCCTG
GCGT 
For PCR Sequencing of ramR in clinical isolates.S4 
ramR R CTGCAGATTTGCTGATTCAGCA
GCGAC 
 604 
605 
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Table S2. Multiplex PCR primers used in this study 606 
Primer Sequence (5'-3') Reference Product size (bp) 
IMP F GGAATAGAGTGGCTTAACTCTC (Poirel et al., 2011)S5 232 
IMP R GGTTTAACAAAACAACCACC 
  VIM F GATGGTGTTTGGTCGCATA (Poirel et al., 2011)S5 390 
VIM R CGAATGCGCAGCACCAG 
  OXA-48 F GCGTGGTTAAGGATGAACAC (Poirel et al., 2011)S5 438 
OXA-48 R CATCAAGTTCAACCCAACCG 
  NDM F GGTTTGGCGATCTGGTTTTC (Poirel et al., 2011)S5 621 
NDM R CGGAATGGCTCATCACGATC 
  KPC F CGTCTAGTTCTGCTGTCTTG (Poirel et al., 2011)S5 798 
KPC R CTTGTCATCCTTGTTAGGCG 
  TEM F CCGAAGAACGTTTTCCAATG This study 249 
TEM R GTCCTCCGATCGTTGTCAGAA 
  SHV F CTTTCCCATGATGAGCACCT This study 127 
SHV R GCGAGTAGTCCACCAGATCC 
  OXA-1 F TTATCTACAGCAGCGCCAGT This study 451 
OXA-1 R AAGCTACTTTCGAGCCATGC 
  CMY (G1) F  CGATCCGGTCACGAAATACT This study 556 
CMY (G1) R  CCAGCCTAATCCCTGGTACA 
  CTX-M (G1) F AAAAATCACTGCGCCAGTTC (Woodford et al., 2006)S6 415 
CTX-M (G1) R AGCTTATTCATCGCCACGTT 
  CTX-M (G2) F CGACGCTACCCCTGCTATT (Woodford et al., 2006)S6 552 
CTX-M (G2) R CCAGCGTCAGATTTTTCAGG 
  CTX-M (G8) F TCGCGTTAAGCGGATGATGC (Woodford et al., 2006)S6 666 
CTX-M 
(G8/25) R AACCCACGATGTGGGTAGC 
  CTX-M (G9) F CAAAGAGAGTGCAACGGATG (Woodford et al., 2006)S6 205 
CTX-M (G9) R ATTGGAAAGCGT TCATCACC 
  CTX-M (G25) F GCACGATGACATTCGGG (Woodford et al., 2006)S6 327 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
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Table S3. β-lactamase activity in Ecl8ΔramR transformants versus Ecl8 transformants carrying 614 
the same β-lactamase gene. 615 
 616 
 
Ecl8 
 
Ecl8ΔramR 
 
Mean SEM Mean SEM 
pSU18 7.56 4.53 8.70 8.14 
pSU(IMP) 193.57 13.61 257.02 31.56 
pSU(OXA) 111.50 4.05 89.80 6.59 
pSU(CTX) 54.19 4.48 41.59 7.18 
pSU(VIM) 227.49 34.16 142.35 5.62 
pSU(CMY) 36.05 2.79 16.12 4.60 
pSU(NDM) 51.80 6.13 52.93 6.71 
pSU(KPC) 231.32 22.07 317.29 34.57 
 
     
617 
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Table S4. Impact of β-lactamase carriage and ramR mutation on β-lactam susceptibility in K.  618 
 pneumoniae clinical isolates 619 
 620 
Strain FOX CXM CTX CAZ FEP ATM IPM MEM DOR ETP Cephalosporinase/Carbapenemase 
Genes 
RamR 
Mutation 
ramA 
expression 
(mean +/- 
SEM) 
Y 6 6 6 6 6 6 10 6 6 6 CTX-M Group 1, OXA-48-like, NDM Lys9Ile 12.7 +/- 2.5 
X 6 6 10 6 7 6 10 6 6 6 KPC Ala40Val 43.6 +/- 8.7 
D 6 6 6 6 6 27 11 8 8 6 VIM 
  C 7 6 6 14 9 8 16 10 11 6 CTX-M Group 1, OXA-48-like  Met184Val 4.3 +/- 1.0 
T 8 6 6 11 6 6 25 23 21 17 CTX-M Group 1 Lys63 FS 45 +/- 6.3 
E 24 6 6 6 8 6 28 30 28 24 CTX-M Group 1 Thr141Ile 
 G 23 6 9 16 13 14 25 29 24 27 CTX-M Group 1 
  AQ 23 6 10 15 19 13 26 27 27 23 CTX-M Group 1 Thr141Ile 
 K 25 6 10* 18 18 17 25 29 26 27 CTX-M Group 1 Thr141Ile 
 S 24 6 9 17 16 12 25 30 25 27 CTX-M Group 1 Thr141Ile 
 AB 23 6 11 18 16 14 24 28 24 28 CTX-M Group 1 
  AC 25 6 8 17 15 13 24 30 24 30 CTX-M Group 1 Thr141Ile 
 W 24 6 10 16 17 10 26 29 27 28 CTX-M Group 1 Thr141Ile 
 I 24 6 10* 19 19 17 27 30 27 29 CTX-M Group 1 Thr141Ile 
 Q 25 6 10 18 17 14 25 30 26 27 CTX-M Group 1 
  AA 25 6 11 18 17 15 26 28 26 29 CTX-M Group 1 
  P 26 6 11 18 17 17 25 29 26 28 CTX-M Group 1 Thr141Ile 
 O 25 6 12 18 19 17 25 29 26 28 CTX-M Group 1 Thr141Ile 
 L 25 6 11 20 21 18 25 29 25 28 CTX-M Group 1 Thr141Ile 
 B 25 6 13 20 18 17 24 29 27 30 CTX-M Group 1 Thr141Ile 
 M 22 6 16 20 22 17 25 29 26 28 CTX-M Group 1 Thr141Ile 
 R 27 6 12 19 21 18 26 30 26 27 CTX-M Group 1 Thr141Ile 
 AD 26 6 11 21 19 19 27 29 25 30 CTX-M Group 1 
  F 26 6 13 20 21 20 25 30 25 30 CTX-M Group 1 
  J 25 6 14 23 21 22 25 30 27 27 CTX-M Group 1 Ala19Val 1.0 +/- 0.1 
N 16 18 29 26 29 29 28 31 28 28 
 
Arg44 FS 70.6 +/- 19.1 
AE 23 21 27 29 31 31 25 25 25 25 
 
Thr141Ile 0.8 +/- 0.1 
Z 18 18 28 28 30 30 27 29 27 30 
 
Thr141Ile 
 AJ 23 22 28 29 31 32 27 24 27 25 
 
Thr141Ile 
 V 22 22 31 29 28 30 25 30 26 30 
   AR 20 21 28 28 30 31 27 30 28 30 
 
Thr141Ile 
 U 21 20 30 27 31 32 29 30 28 29 
 
Thr141Ile 
 AI 24 23 31 27 30 32 25 30 27 28 
   AG 23 22 31 26 30 33 26 31 28 29 
   AN 25 25 34 27 29 31 23 31 25 30 
   AF 23 24 30 28 31 34 26 29 27 29 
 
Ala19Val 
 AH 26 25 31 28 31 32 25 30 26 28 
  
CONTROL 
H 26 23 31 28 31 33 26 29 27 30 
 
Thr141Ile 
 A 26 21 32 29 32 33 26 28 27 31 
   AP 24 23 32 30 32 33 27 30 27 29 
 
Thr141Ile 
 AK 25 27 33 29 31 33 25 30 25 30 
 
Ile106Ser 0.7 +/- 0.1 
AO 28 21 32 28 30 32 26 33 28 31 
 
Thr50Ala 4.7 +/- 0.7 
AM 23 24 34 29 32 33 26 32 27 31 
   AL 26 26 34 29 32 33 26 31 26 30 
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Abbreviations: FOX, cefoxitin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; FEP, 621 
cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; DOR, doripenem; ETP, 622 
ertapenem. 623 
Inhibition zone diameters were determined as per the CLSI methodology 13 and interpreted as 624 
susceptible (blue), intermediate (green) or resistant (yellow) as per CLSI breakpoints.14 625 
ramA expression levels measured are by reference to the control isolate AH. 626 
627 
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Table S5 – Envelope proteome changes following overproduction of RamA in K. pneumoniae 628 
Ecl8 during growth in Muller-Hinton Broth. 629 
Accession Description Ecl8 E1 Ecl8 E2 Ecl8 E3 Ecl8 Δ E1 Ecl8 Δ E2 Ecl8 Δ E3 T-Test Fold 
Change 
A6T4W5 DegP Serine Protease 2.30E+08 2.54E+08 2.44E+08 9.26E+08 4.59E+08 4.51E+08 0.039 2.52 
A6T5M4 AcrB 1.38E+08 6.59E+08 5.71E+08 7.98E+08 3.17E+09 2.69E+09 0.038 4.87 
A6T5M5 AcrA 2.96E+09 2.35E+09 2.33E+09 1.20E+10 7.66E+09 1.00E+10 0.002 3.88 
A6T5Q5 Putative Outer Membrane Protein 1.08E+07   6.78E+07 4.26E+07 7.87E+07 <0.001 5.85 
A6T5Y8 Mg2+ Transport ATPase 3.16E+07 5.03E+07 7.98E+07 9.69E+07 2.01E+08 2.05E+08 0.020 3.11 
A6T6B0 Periplasmic Binding Protein GltI 6.47E+07 4.94E+07 2.01E+07    <0.001 0.05 
A6T6D9 Potassium-transporting ATPase KdpA 2.19E+08 1.80E+08 4.06E+08    <0.001 0.05 
A6T6K5 Putative cation transport protein  5.00E+06 9.22E+06  6.51E+07 7.52E+07 0.004 9.87 
A6T6W3 Putative lipoprotein YbjP 8.94E+08 7.67E+08 6.96E+08 5.15E+09 3.41E+09 3.95E+09 0.001 5.30 
A6T721 OmpK35 2.70E+10 2.14E+10 1.77E+10 1.17E+10 6.97E+09 9.95E+09 0.007 0.43 
A6T7Z9 ABC Transporter SapF    1.38E+08 6.33E+07 7.30E+07 <0.001 20.00 
A6T8F9 Heat shock protein HslJ    2.73E+08 1.87E+08 1.97E+08 <0.001 20.00 
A6T9Y7 Uncharacterized protein YdhA 3.57E+07 3.03E+07 2.54E+07 2.94E+08 1.27E+08 1.43E+08 0.021 6.17 
A6TAW2 Cell Volume Regulation Protein A 1.93E+07 5.96E+07 6.18E+07 1.43E+08 1.05E+08 7.99E+07 0.026 2.33 
A6TB10 Putative Enzyme  3.00E+07 3.81E+07 1.57E+07    <0.001 0.05 
A6TBM0 D-ala-D-alanine endopeptidase PbpG    2.93E+07 7.95E+07 2.11E+07 <0.001 20.00 
A6TCA4 Putative permease PerM 1.62E+07 3.26E+07 6.06E+07  1.28E+08 1.58E+08 0.007 3.92 
A6TCQ4 OqxA    7.10E+07 8.78E+07 6.32E+07 <0.001 20.00 
A6TCQ5 OqxB    3.09E+07 6.46E+07 2.97E+07 <0.001 20.00 
A6TCT2 Putative Uncharacterized Protein 3.49E+08 2.57E+08 2.44E+08 1.50E+09 6.85E+08 1.27E+09 0.012 4.06 
A6TE24 TolC 3.33E+09 2.53E+09 2.88E+09 1.17E+10 7.49E+09 8.30E+09 0.004 3.15 
A6TF45 Glycerol-3-Phosphate 
Dehydrogenase GlpD 
2.00E+07 9.77E+07 8.46E+06 6.82E+08 3.69E+08 7.45E+08 0.005 14.23 
A6TGU2 Maltose ABC transport protein MalG  2.48E+08 1.81E+08  4.83E+07 3.80E+07 0.018 0.20 
A6TGU4 Maltose-Binding Protein MalE 6.95E+07 2.19E+08 2.32E+08 5.84E+07 5.02E+07 7.54E+07 0.050 0.35 
A6TGU6 Maltoporin LamB2 5.39E+09 1.35E+10 1.42E+10 3.74E+09 3.86E+09 4.03E+09 0.032 0.35 
A6TH80 Putative Periplasmic Protein 4.27E+07 2.53E+07 2.65E+07    <0.001 0.05 
A6THB7 Peptidyl-Prolyl cis-trans Isomerase 
FklB 
2.59E+08 2.26E+08 4.01E+08    <0.001 0.05 
A6THB8 D-alanine/D-serine/glycine 
Transporter CycA 
 2.32E+08 2.46E+08 4.63E+07 5.82E+07 1.68E+08 0.030 0.38 
A6THT5 Putative porin 9.11E+08 8.09E+08 6.17E+08 2.46E+09 1.49E+09 2.04E+09 0.007 2.56 
Absolute protein abundance data are reported for three experiments (E1, E2 and E2), each 630 
from a different batch of cells of Ecl8 or Ecl8ΔramR (Ecl8 Δ). Data are analysed as explained in 631 
Supplementary Methods, above. Proteins highlighted in Green are significantly regulated (up or 632 
down) during the growth conditions used to generate the data in Table S6. Proteins highlighted 633 
in blue are also significantly regulated during the growth conditions used to generate the data 634 
in Table S7. 635 
636 
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Table S6 – Envelope proteome changes following overproduction of RamA in K. pneumoniae 637 
Ecl8 during growth in Nutrient Broth. 638 
Accession Description Ecl8 E1 Ecl8 E2 Ecl8 E3 Ecl8 Δ E1 Ecl8 Δ E2 Ecl8 Δ E3 T-Test Fold 
Change 
A6T4P6 GMP reductase GuaC  1.41E+08 1.46E+07 8.29E+06 1.15E+08   <0.001 2.10 
A6T4Q8 Dihydrolipoamide acetyltransferase 
AceF  
1.69E+09   1.39E+09 1.54E+07 1.61E+07 <0.001 0.28 
A6T5J2 ABC transporter MdlA  1.20E+07 1.21E+07 1.37E+07 4.44E+07 2.64E+07 2.31E+07 0.024 2.48 
A6T5M4 AcrB  3.23E+08 1.42E+08 1.46E+08 2.20E+09 7.76E+08 8.12E+08 0.044 6.21 
A6T5M5 AcrA 1.91E+09 9.54E+08 6.59E+08 4.20E+09 4.23E+09 3.45E+09 0.002 3.38 
A6T5Q5 Putative outer membrane protein    5.99E+07 6.50E+07 4.62E+07 <0.001 20.00 
A6T6Q4 ABC transporterer GlnP     3.92E+07 6.19E+07 5.86E+07 <0.001 20.00 
A6T6W3 Putative lipoprotein YbjP 3.11E+08 4.07E+08 1.86E+08 1.68E+09 2.72E+09 1.94E+09 0.002 7.01 
A6T721 OmpK35 2.48E+10 1.33E+10 9.85E+09 4.01E+09 3.45E+09 3.42E+09 0.026 0.23 
A6T7Y0 Putative peptidase SohB  1.24E+08 5.59E+07 5.11E+07 1.51E+08 1.89E+08 1.39E+08 0.020 2.08 
A6T7Z9 ABC Transporter SapF    4.45E+07 2.15E+07 1.75E+07 <0.001 20.00 
A6T813 Putative enzyme YcjX     4.53E+07 5.68E+06 2.85E+06 <0.001 20.00 
A6T8F9 Heat shock protein HslJ     4.83E+07 1.47E+08 4.82E+07 <0.001 20.00 
A6T9P0 Nitrate reductase NarZ  1.10E+08 1.55E+08 3.92E+07 1.52E+08 2.07E+08 3.07E+08 0.050 2.19 
A6T9W1 Glucose dehydrogenase     2.52E+07 7.99E+06 1.15E+07 <0.001 20.00 
A6T9Y7 Putative uncharacterized protein 
YdhA 
   6.58E+07 1.03E+08 8.57E+07 <0.001 20.00 
A6TAG5 Putative oxidase YdiJ   1.34E+07  5.38E+07 4.88E+07 2.09E+07 <0.001 3.06 
A6TB64 Response regulator UvrY 1.26E+08   1.77E+08 7.77E+06 5.48E+06 <0.001 0.50 
A6TBL5 Beta-D-glucoside glucohydrolase 1.58E+08   1.35E+08 1.15E+07 3.62E+07 <0.001 0.39 
A6TC20 3-ketoacyl-CoA thiolase  4.97E+07 1.24E+07 1.06E+07    <0.001 0.05 
A6TC59 Sulfate permease CysA   1.33E+07 1.22E+07  3.37E+07 3.39E+07 0.000 2.65 
A6TCQ4 OqxA    1.15E+07 1.09E+07 1.56E+07 <0.001 20.00 
A6TCQ5 OqxB    1.28E+07 1.64E+07 1.54E+07 <0.001 20.00 
A6TCT2 Putative uncharacterized protein 5.93E+07 5.37E+07 7.11E+07 3.03E+08 3.27E+08 2.96E+08 <0.001 5.03 
A6TE24 TolC 2.23E+09 1.20E+09 8.93E+08 6.81E+09 4.91E+09 3.44E+09 0.013 3.51 
A6TEC8 Serine/threonine transporter SstT  4.48E+07 1.16E+07 1.86E+07   8.35E+06 <0.001 0.33 
A6TEI6 Ribosome-binding factor A  6.73E+07 2.02E+07 1.70E+07 1.46E+08   <0.001 4.18 
A6TEL1 Putative ABC Transporter YrbC  7.98E+06 2.00E+07 8.85E+07 5.39E+07 3.82E+07 0.050 4.30 
A6TEL2 Putative ABC Transporter YrbD PE=4 
SV=1 - [A6TEL2_KLEP7] 
2.31E+08 2.97E+08 2.21E+08 6.21E+08 7.01E+08 6.00E+08 0.000 2.57 
A6TEL3 Putative ABC Transporter YrbE  1.17E+07 1.42E+07  3.52E+07 4.21E+07 0.010 2.99 
A6TEL4 Putative ABC Transporter YrbF  5.97E+07 6.79E+07 2.24E+08 1.51E+08 1.33E+08 0.031 2.65 
A6TET0 AcrE  3.74E+08 2.73E+08  1.23E+09 1.29E+09 0.002 3.89 
A6TET1 AcrF    2.58E+08 1.36E+08 1.34E+08 <0.001 20.00 
Absolute protein abundance data are reported for three experiments (E1, E2 and E2), each 639 
from a different batch of cells of Ecl8 or Ecl8ΔramR (Ecl8 Δ). Data are analysed as explained in 640 
Supplementary Methods, above. Proteins highlighted in Green are significantly regulated (up or 641 
down) during the growth conditions used to generate the data in Table S5. Proteins highlighted 642 
in orange are also significantly regulated during the growth conditions used to generate the 643 
data in Table S7. 644 
645 
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Table S7 – Envelope proteome changes following overproduction of RamA in K. pneumoniae 646 
NCTC5055 using the pBAD expression vector during growth in Nutrient Broth. 647 
 648 
Accession Description pBAD E1 pBAD E2 pBAD E3 RamA E1 RamA E2 RamA E3 T-Test Fold 
Change 
A6T4S4 Putative ATP transporter YadG 9.22E+07 1.04E+08 1.47E+08 6.21E+08 3.10E+08 4.80E+08 0.01 4.11 
A6T4W5 Periplasmic serine protease DegP 1.36E+08 1.13E+08 3.83E+07 2.04E+08 2.02E+08 2.86E+08 0.01 2.41 
A6T4X8 Membrane-associated protease YaeL 8.49E+07 1.75E+07 2.92E+07 1.15E+08   <0.001 2.61 
A6T5A1 Uncharacterized protein YaiW   7.80E+06 9.83E+07 1.82E+07 3.86E+07 <0.001 6.64 
A6T5M4 AcrB 1.12E+09 8.70E+07 9.87E+07 4.52E+09 9.67E+08 3.34E+09 0.04 6.74 
A6T5M5 AcrA 1.86E+09 5.63E+08 4.27E+08 1.49E+10 4.92E+09 7.87E+09 0.03 9.73 
A6T5Q5 Putative outer membrane protein    1.36E+08 2.25E+08 1.07E+08 <0.001 >20 
A6T5S5 Lipid A biosynthesis protein    2.96E+08 6.11E+07 1.57E+08 <0.001 >20 
A6T5S9 Lysine decarboxylase CadA 5.09E+07 1.45E+08 2.03E+07    <0.001 <0.05 
A6T5Y2 Nitroreductase NfnB    5.85E+07 5.07E+07 2.99E+07 <0.001 >20 
A6T5Y5 Putative regulatory protein    4.56E+08 1.93E+08 2.59E+08 <0.001 >20 
A6T689 Lipoyl synthase LipA 1.36E+08 1.05E+08 2.10E+07 3.43E+08 3.89E+08  0.00 4.20 
A6T694 Minor lipoprotein RlpA 1.46E+08 6.95E+07 4.97E+07 1.78E+08   <0.001 2.02 
A6T6W2 Putative ABC transport protein ArtP    2.33E+08 1.08E+08 2.01E+08 <0.001 >20 
A6T6W3 Putative lipoprotein YbjP 3.57E+08 1.96E+08 4.29E+08 8.42E+09 3.82E+09 9.74E+09 0.01 22.40 
A6T746 Putative protein YmbA 1.24E+08 4.55E+07 8.41E+07 3.88E+08 1.77E+08 3.76E+08 0.02 3.71 
A6T7Y0 Putative peptidase SohB 1.42E+08 4.68E+07 7.32E+07 5.98E+08 2.49E+08 5.11E+08 0.01 5.19 
A6T8F7 Oxidoreductase YdbK 2.29E+07   8.86E+07 3.34E+08 6.50E+07 <0.001 7.08 
A6T8F9 Heat shock protein HslJ    2.41E+09 8.45E+08 1.95E+09 <0.001 >20 
A6T8N5 Putative protein YdgH 1.03E+08 1.25E+08 9.58E+07 3.31E+08 1.23E+08 2.73E+08 0.05 2.25 
A6T961 Putative regulatory protein DeoR 1.00E+08 8.53E+07 1.44E+08 2.94E+07 6.08E+07  0.04 0.41 
A6T963 Putative pentose kinase 8.11E+07 6.20E+07 7.69E+06    <0.001 <0.05 
A6T9L3 Alcohol dehydrogenase AdhP  1.97E+07 1.32E+07 3.99E+07 5.44E+07 6.33E+07 0.01 3.20 
A6T9Y7 Putative protein YdhA 1.65E+08 7.58E+07 4.97E+07 6.63E+08 1.73E+08 5.42E+08 0.04 4.75 
A6TAP0 Glutamyl-tRNA reductase HemA 1.40E+08 1.93E+07 4.53E+07 1.71E+08   <0.001 2.51 
A6TBQ3 Putative enzyme YeiR    3.75E+07 4.09E+07 3.43E+07 <0.001 >20 
A6TC64 Putative uncharacterized protein YfeY   4.74E+07 2.31E+08  1.31E+08 <0.001 3.81 
A6TCA4 Putative permease PerM    3.43E+08 5.25E+07 2.29E+08 <0.001 >20 
A6TCI0 GTPase Era  8.89E+07 8.89E+07 6.94E+06 1.55E+08 1.37E+08  0.05 2.37 
A6TCQ4 OqxA    7.75E+07 5.51E+07 8.69E+07 <0.001 >20 
A6TCQ5 OqxB    1.50E+08 2.13E+07 9.34E+07 <0.001 >20 
A6TCT2 Putative uncharacterized protein 1.87E+08 9.32E+07 6.25E+07 1.79E+09 7.68E+08 7.58E+08 0.02 9.67 
A6TE24 TolC 1.63E+09 9.81E+08 1.45E+09 1.29E+10 3.17E+09 7.03E+09 0.04 5.67 
A6TEC6 Putative dehydrogenase YgjR    6.10E+07 6.97E+07 6.35E+07 <0.001 >20 
A6TEH9 Putative enzyme YhbW    1.04E+08 3.46E+08 3.18E+08 <0.001 >20 
A6TEL0 Putative protein YrbB    2.14E+08 7.54E+07 1.38E+08 <0.001 >20 
A6TEL1 Putative ABC transport protein YrbC 5.45E+07 3.55E+07 4.27E+07 1.02E+08 8.96E+07 1.04E+08 0.00 2.23 
A6TEL2 Putative ABC transport protein YrbD 5.73E+08 2.29E+08 2.01E+08 3.31E+09 9.12E+08 2.08E+09 0.03 6.28 
A6TEL3 Putative ABC transport protein YrbE 1.16E+08  5.29E+07 4.30E+08  4.39E+08 0.00 5.16 
A6TEL4 Putative ABC transport protein YrbF 1.73E+08 6.02E+07 9.25E+07 7.47E+08 3.20E+08 6.00E+08 0.01 5.11 
A6TET0 AcrE  1.04E+08  3.01E+09 3.94E+08 1.61E+09 <0.001 16.10 
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A6TET1 AcrF 1.82E+08 1.10E+08 2.21E+08 9.57E+08 2.81E+09 8.41E+08 0.05 8.99 
A6TEZ2 Putative enzyme YheT   7.29E+06 5.19E+07 3.84E+07 6.11E+07 <0.001 6.92 
A6TG29 Phosphate transport protein PstB 2.82E+07 3.56E+07 1.55E+07 8.19E+07 4.81E+07  0.04 2.46 
A6TG98 Putative glycoprotein 1.55E+08 4.46E+07 9.57E+06    <0.001 <0.05 
A6TH72 Succinate dehydrogenase FrdB 6.93E+07 1.22E+08 2.03E+08 5.38E+07 3.61E+07 2.29E+07 0.04 0.29 
A6TH73 Fumarate reductase FrdA 1.20E+08 1.54E+08 3.21E+08 7.69E+07 5.78E+07 4.52E+07 0.05 0.30 
A6THK0 Putative alcohol dehydrogenase YjgB    4.44E+08 3.93E+08 7.85E+07 <0.001 >20 
A6THQ0 Putative uncharacterized protein   2.95E+07 6.08E+08  6.16E+07 <0.001 11.34 
A6THX3 Replication protein DnaC 1.14E+07 8.25E+06 7.71E+06    <0.001 <0.05 
A6TI57 ATPase with chaperone activity 7.63E+08 2.12E+08 2.93E+07    <0.001 <0.05 
 649 
Absolute protein abundance data are reported for three experiments (E1, E2 and E2), each 650 
from a different batch of cells carrying the pBAD(control) or pBAD(RamA) plasmids.5 Data are 651 
analysed as explained in Supplementary Methods, above. Proteins highlighted in Green are 652 
significantly regulated (up or down) during the growth conditions used to generate the data in 653 
Table S5 and S6. Proteins highlighted in blue are also significantly regulated during the growth 654 
conditions used to generate the data in Table S5 only. Proteins highlighted in orange are also 655 
significantly regulated during the growth conditions used to generate the data in Table S6 only. 656 
657 
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Table S8. Disc susceptibility assay for K. pneumoniae Ecl8 transformants with and without 658 
micF overexpression 659 
 660 
Antibiotic (μg in disc) pK18(control) 
Zone (mm) 
pK18(micF) 
[Difference from 
Control] (mm) 
Amikacin (30) 25 +3 
Gentamicin (10) 25 NC 
Tobramycin (10) 24 +4 
Cefoxitin (30) 26 +5 
Cefuroxime (30) 30 NC 
Ceftriaxone (30) 35 NC 
Cefotaxime (30) 35 +5 
Ceftazidime (30) 30 +8 
Cefepime (30) 34 +6 
Aztreonam (30) 40 NC 
Imipenem (10) 30 +5 
Meropenem (10) 30 +5 
Doripenem (10) 30 +5 
Ciprofloxacin (5) 36 +2 
Norfloxacin (10) 32 +6 
Ofloxacin (5) 30 +5 
Tigecycline (15) 23 +2 
Minocycline (30) 23 +2 
Chloramphenicol (30) 28 -2 
Trimethoprim/ 
Sulfamethoxazole 
(1.25/23.75) 
28 +3 
 661 
Assays were performed using Muller Hinton agar containing 30 mg/L kanamycin to select for 662 
the plasmid. Otherwise, the assay was performed according to the CLSI protocol.13 Abbreviation 663 
used is NC: No Change in zone diameter versus control. Values reported are the means of at 664 
least three repetitions rounded to the nearest integer. Mean changes <2 mm are reported as 665 
NC. 666 
 
 
      
